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ABSTRACT
Background: Various mediators, such as thrombox-
ane (TX) A2, peptide leukotrienes (P-LT) and histamine,
are involved in allergic nasal obstruction. The aim of
the present study was to investigate the mechanism
whereby olopatadine hydrochloride, a novel anti-allergic
drug, ameliorated the allergic nasal obstruction.
Methods: The levels of TXB2, P-LT and histamine in
nasal lavage fluid (NLF) were measured after intra-
nasal antigen challenge in sensitized guinea pigs.
Results: Histamine and TXB2 levels in the NLF increased
eight- and threefold, respectively, 10 min after antigen
challenge, whereas the P-LT level was under the detec-
tion limit. Oral administration of olopatadine at 0.1, 
1 and 3 mg/kg significantly inhibited the increases in
TXB2 and histamine levels. At 3 mg/kg, olopatadine
also ameliorated the nasal obstruction caused 10 min
after antigen challenge, as determined by acoustic
rhinometry.
Conclusions: These results suggest that the ameliora-
tion by olopatadine of the allergic nasal obstruction
involves the inhibition of the release of TXA2 and 
histamine.
Key words: allergic rhinitis, chemical mediators,
guinea pigs, olopatadine.
INTRODUCTION
Thromboxane (TX) A2 and peptide leukotrienes (P-LT), as
well as histamine, are involved in the pathogenesis of
allergic nasal obstruction.1–6 These mediators in nasal
lavage fluid (NLF) are reported to be increased after
antigen challenge in allergic human patients,1,2 as well 
as in sensitized guinea pigs.2–4 The intranasal application
of U-46619, a stable TXA2 mimetic, P-LT or histamine 
is known to cause nasal obstruction.3 Moreover, rama-
troban,5 a TXA2 receptor antagonist, and pranlukast,6 a
P-LT receptor antagonist, have been demonstrated to
ameliorate nasal obstruction in allergic rhinitis patients.
Olopatadine hydrochloride ((Z)-11-(3-dimethylamino-
propylidene)-6,11-dihydrobenz[b,e]oxepin-2-acetic acid
monohydrochloride; CAS 140462-76-6; KW-4679) is a
novel drug for the treatment of allergic diseases. Olopa-
tadine has an antagonistic action against the histamine
H1 receptor.7 A previous in vitro study demonstrated that
olopatadine inhibited histamine release from rat peri-
toneal mast cells following the antigen–antibody reaction.8
Moreover, olopatadine inhibits TXB2 release from human
neutrophils and P-LT release from guinea pig eosinophils.9
Olopatadine has been shown to ameliorate the nasal
symptoms of allergic rhinitis, including nasal obstruction,
in humans,10 as well as in guinea pigs.11
In the present study, we determined the concentrations
of TXB2, P-LT and histamine in NLF after intranasal
antigen challenge in passively sensitized guinea pigs 
in order to elucidate whether olopatadine inhibits the
release of these mediators from the nasal mucosa in vivo.
We also examined the effects of ketotifen, an anti-allergic
drug, on the release of the mediators because keto-
tifen, as well as olopatadine, inhibited allergic nasal
obstruction in guinea pigs.11 In addition, in the present
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study we confirmed the inhibition of nasal obstruction
by olopatadine.
METHODS
Materials
Olopatadine was synthesized at the Sakai Research
Laboratories of Kyowa Hakko Kogyo (Osaka, Japan).
Ketotifen fumarate (ketotifen) was purchased from Sigma
Chemical (St Louis, MO, USA). Other reagents used were
ovalbumin (OVA; Sigma Chemical), carbamic acid ethyl-
ester (urethane; Tokyo Kasei, Tokyo, Japan), indomethacin
(Sigma Chemical), EDTA and AA-861 (Wako Pure
Chemical Industries, Osaka, Japan).
Sensitization
Male 5-week-old Hartley guinea pigs (Japan SLC,
Shizuoka, Japan) were passively sensitized by intravenous
injections of guinea pig anti-OVA antiserum in a volume
of 1 mL/kg bodyweight. The antiserum was prepared by
immunizing guinea pigs subcutaneously with 10 µg OVA
and 1 mg alum. An additional injection was performed 
3 weeks later and blood was collected 1 week after the
injection. The antibody titer in the serum, determined by
the 8 day homologous passive cutaneous anaphylaxis,
was 64. The antibody in serum was inactivated by heating
at 56°C for 2 h and, thus, the serum was confirmed to
contain the IgE antibody.
Measurement of mediators
Eight days after passive sensitization, animals were
anesthetized with urethane (1.2 g/kg, i.p.) and a can-
nula was inserted from the trachea into the nasal cavity.
The antigen was challenged by applying 20 µL OVA
solution (1% w/v in saline) into each nasal cavity
through each nostril. In the sham group, saline, instead
of the OVA solution, was applied intranasally. Olopa-
tadine, ketotifen or distilled water was administered
orally 1 h before the intranasal antigen challenge.
Distilled water was administered in the control and
sham groups. Ten minutes after antigen challenge, the
nasal cavity was perfused with saline at a rate of 
0.3 mL/min and the NLF was collected into a tube, con-
taining indomethacin (10 µmol/L), the 5-lipoxygenase
inhibitor AA-861 (1 µmol/L) and EDTA (7.7 mmol/L),
for 10 min. These three reagents were added to block
the release of TXA2, P-LT and histamine, respectively,
from inflammatory cells into the NLF in the tube. The
supernatants obtained after centrifugation were used for
analyses.
The concentration of TXB2 has been determined to
study the dynamics of TXA2 because TXA2 is degraded 
to the stable product TXB2. The concentrations of TXB2
and P-LT were measured by enzyme immunoassay
(Cayman, Ann Arbor, MI, USA) and radioimmunoassay
(Amersham, Little Chalfont, UK), respectively, after pre-
treatment of samples as follows. Samples were mixed
with ethanol and centrifuged and the supernatants were
applied to Sep-pak C18 columns (Waters, Milford, MA,
USA) and eluted into ethyl acetate containing methanol
for the measurement of TXB2 or into methanol for mea-
surement of P-LT. The concentration of histamine was
measured by radioimmunoassay (Eiken Kagaku, Tokyo,
Japan) without pretreatment of the samples. The detec-
tion limits for TXB2, P-LT and histamine were 0.2 pg/mL,
156 pg/mL and 0.06 ng/mL, respectively.
Evaluation of nasal obstruction
Eight days after passive sensitization, nasal obstruction
was evaluated by observing the decrease in nasal cavity
volume, which was measured by acoustic rhinometry 
(GJ Elektronik, Skanderborg, Denmark), in guinea pigs
anesthetized with urethane (1.2 g/kg, i.p.). The details of
the acoustic reflection technique have been reported
elsewhere.12 The volume of the right and left nasal cavi-
ties between the nostril and 2 cm into the nasal cavity
was determined by averaging three measurements. The
nasal obstruction in each animal was evaluated by the
decrease in the total volume of the right and left nasal
cavities. The antigen was challenged by applying 20 µL
OVA solution (1% w/v in saline) into each nasal cavity
through each nostril. In the sham group, saline, instead
of the OVA solution, was applied intranasally. The nasal
cavity volume was measured before and 10 min after
intranasal challenge and nasal obstruction after the chal-
lenge is expressed as a percentage change from the
nasal cavity volume before challenge. Olopatadine 
(3 mg/kg) or distilled water was administered orally 1 h
before the intranasal antigen challenge. Distilled water
was administered to the control and sham groups.
Statistical analysis
Data are shown as the mean±SEM. The Wilcoxon rank
sum test or Student’s t-test were used for analysis of
differences between two groups and the least significant
difference (LSD) test was used for analysis among mul-
tiple groups. P < 0.05 was considered significant.
RESULTS
The concentration of TXB2 in the NLF was higher in the
control group than that in the sham group (185.3 ±
40.5 vs 58.1 ± 14.9 pg/mL, respectively; n = 8). 
The TXB2 concentrations in the olopatadine (0.01–
3 mg/kg) groups and ketotifen (0.01–3 mg/kg) groups
were lower than in the control group. Significant inhibi-
tions were observed following olopatadine at 1 and 
3 mg/kg and ketotifen at 0.1 mg/kg (75.6 ± 21.0,
84.3 ± 25.0 and 57.0 ± 10.7 pg/mL, respectively; 
n = 8; Fig. 1).
The concentration of histamine was higher in the
control group than in the sham group (2.36 ± 0.48 vs
0.28 ± 0.15 ng/mL, respectively; n = 8). The con-
centrations of histamine in the olopatadine (0.01–
3 mg/kg) groups and ketotifen (0.1–3 mg/kg) groups
were lower than in the control group. Olopatadine at
0.1 and 3 mg/kg and ketotifen at 1 mg/kg significantly
inhibited the increase in histamine levels (1.04 ± 0.19,
1.12 ± 0.25 and 1.09 ± 0.31 ng/mL, respectively; 
n = 8; Fig. 2).
The concentration of P-LT in both the control and 
the sham groups was lower than the detection limit
(468 pg/perfusate).
The percentage change in nasal cavity volume 10 min
after intranasal antigen challenge (–14.8 ± 2.8%; 
n = 15) was significantly greater than that after the
intranasal instillation of saline (–2.0 ± 1.6%; n = 15). 
At 3 mg/kg, olopatadine tended to inhibit the decrease 
in nasal cavity volume to –5.3 ± 3.8% (n = 15; Table 1).
DISCUSSION
In the present study, we used a guinea pig model of
nasal allergy induced by passive sensitization, but not by
active sensitization,11 because the concentration of TXB2
released into NLF varies considerably in actively sensi-
tized guinea pigs.2 The present study demonstrated that
olopatadine and ketotifen inhibited the increase in TXB2
and histamine levels in NLF after antigen challenge in
sensitized guinea pigs, indicating that both drugs inhibit
the releases of TXA2 and histamine from the nasal
mucosa. This is the first demonstration that anti-allergic
drugs inhibit TXA2 release from the nasal mucosa in vivo.
The present study failed to detect an increase in P-LT
levels, although P-LT levels in the NLF have been reported
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Fig. 1 Effects of olopatadine and ketotifen on the increase in
thromboxane B2 concentrations in nasal perfusates after
antigen challenge in sensitized guinea pigs. Drugs were admin-
istered orally 1 h before antigen challenge. In the sham group,
saline, instead of the antigen solution, was applied into the
nasal cavity. Results are the mean±SEM of 10 animals in 
the 0.01 mg/kg groups and eight animals in the other groups.
†P < 0.01 compared with the sham group; *P < 0.05, 
‡P < 0.001 compared with the control group.
Fig. 2 Effects of olopatadine and ketotifen on the increase 
in histamine concentrations in nasal perfusates after antigen
challenge in sensitized guinea pigs. Drugs were administered
orally 1 h before antigen challenge. In the sham group, 
saline, instead of the antigen solution, was applied into the
nasal cavity. Results are the mean±SEM of 10 animals in 
the 0.01 mg/kg groups and eight animals in the other groups.
†P < 0.01 compared with the sham group; *P < 0.05 com-
pared with the control group.
to increase 10 min after antigen challenge in humans.1
In contrast, Fujita et al.4 recently demonstrated that 
P-LT levels in the NLF after antigen challenge in sensitized
guinea pigs were 374.5 ± 88.2 pg/lavage, which is
much lower than that in humans1 and slightly lower than
the detection limit in the present study. Further studies,
using a more sensitive analytical method to detect P-LT,
are required to elucidate the effects of olopatadine on 
P-LT release.
In the present study, we demonstrated that the levels of
TXB2 and histamine increased in NLF collected 10 min
after antigen challenge and that olopatadine inhibited
these increases. The increases in TXB2 and histamine
levels 10 min after antigen challenge are consistent with
previous results in guinea pigs2,3 and humans.1,2 Because
the source of both TXA2 and histamine, released immedi-
ately after intranasal antigen challenge, is assumed to be
mast cells,2,3 it seems that olopatadine inhibited the
release of TXA2 and histamine from nasal mast cells.
In in vitro studies, olopatadine inhibited histamine
release from rat peritoneal mast cells at a concentration
of 100 µmol/L.8 The peak plasma drug concentration
was reported to be 3.1 µmol/L after the oral administra-
tion of 3 mg/kg olopatadine,13 a dose that inhibited
histamine release in the present study. The difference 
in the concentrations inhibiting the histamine release
between the in vitro and in vivo studies may be ascribed
to the following two reasons. First, there may be an
involvement of antihistaminergic action in the in vivo,
but not in vitro, inhibition by olopatadine of histamine
release. The intranasal application of histamine releases
neuropeptides from sensory nerves in the nasal mucosa,14
while substance P, one of the neuropeptides released,
stimulates nasal mast cells to release histamine.15 These
results suggest that histamine, once released from nasal
mast cells, can stimulate sensory nerves to potentiate the
release of histamine in a positive-feedback manner. It is
thus possible that the antagonistic action of olopatadine
against histamine H1 receptors contributes to the inhibi-
tion of histamine release in the nasal mucosa, although
the antagonism against H1 receptors may inhibit only the
secondary histamine release mediated by the neuro-
peptides and not the primary release immediately after
the antigen–antibody reaction. Second, the direct inhibi-
tory effect of olopatadine on neruopeptide release16
may have contributed to the in vivo inhibition of hista-
mine release. As mentioned above, the inhibition of
neruopeptide release is assumed to inhibit the neuro-
peptide-mediated histamine release. These effects of
olopatadine, in addition to its direct action on mast cells,8
may have played a role in the inhibition of histamine
release in vivo.
In the present study, olopatadine tended to ameliorate
nasal obstruction at a dose of 3 mg/kg, the dose that
inhibited the release of both TXA2 and histamine. The
study by Nabe et al.17 demonstrated that the histamine 
H1 receptor antagonist mepyramine did not affect nasal
obstruction caused 10 min after intranasal antigen chal-
lenge in passively sensitized guinea pigs, suggesting that
the blockade of histamine H1 receptors alone is not suffi-
cient to inhibit nasal obstruction. Indeed, although the
histamine H1 receptor antagonist is the first choice of 
recommended therapy in mild cases of allergic rhinitis,18
it has only limited therapeutic effects on nasal obstruc-
tion.19 It is thus possible that olopatadine inhibited nasal
obstruction by its inhibition of TXA2 and histamine release
and not solely by its antagonistic action against hista-
mine H1 receptors. Considering the suppressive action of
ramatroban against nasal obstruction,5 it is assumed
that the amelioration by olopatadine of nasal obstruc-
tion involves its inhibitory effect on TXA2 release.
However, histamine H2 and H3 receptors, as well as 
H1 receptors, are reported to have significant roles in
the pathogenesis of nasal obstruction.20–22 These results
suggest that the inhibition of histamine release has some
advantage over the antagonism against H1 receptor in
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Table 1 Effect of olopatadine on the decrease in the nasal cavity volume after antigen challenge in sensitized guinea pigs
Group % Volume change P* % Inhibition
Sham –2.0 ± 1.6 0.0005
Control –14.8 ± 2.8
Olopatadine (3 mg/kg, p.o.) –5.3 ± 3.8 0.0526 74.2
Data are the mean±SEM of 15 animals.
*P values are for comparisons with the control group.
Olopatadine or its vehicle was administered orally 1 h before antigen challenge. In the sham group, saline, instead of the antigen solution, was
applied intranasally.
the treatment of nasal obstruction, because the former
is supposed to result in inhibited responses mediated by
H2 and H3 receptors in addition to H1 receptors. Thus,
olopatadine, which inhibits both TXA2 and histamine
release from the nasal mucosa, is assumed to be an
effective drug in the treatment of nasal obstruction in
allergic rhinitis patients. In fact, olopatadine has been
shown to prominently ameliorate nasal obstruction in
humans.10
In conclusion, we have elucidated that olopatadine
inhibits the release of TXA2 and histamine from guinea
pig nasal mucosa after antigen challenge. The inhibited
release of TXA2 and histamine is suggested to be involved
in the amelioration by olopatadine of allergic nasal
obstruction.
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